A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients

NCT ID: NCT04048811

Last Updated: 2020-12-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-09
• Study Completion Date: 2020-06-22

Brief Summary

This is a multi-center, randomized, open-label, positive-controlled (propofol) phase II clinical trial. The study plans to enroll approximately 46 eligible subjects. Among them, 40 subjects will be randomly assigned to HSK3486 treatment group (30 cases) and propofol control group (10 cases) in a ratio of 3:1. The subjects will be enrolled competitively at all study sites. Upon enrollment of the 40 subjects, 6 more subjects will be enrolled by West China Hospital of Sichuan University. These 6 subjects will not be randomized, but will directly enter into propofol induction + HSK3486 maintenance group for study.

Conditions

Induction and Maintenance of General Anesthesia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HSK3486

HSK3486 induction + maintenance group

Group Type: EXPERIMENTAL

HSK3486

Intervention Type: DRUG

The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.

Propofol

Propofol induction + maintenance group

Group Type: ACTIVE_COMPARATOR

Propofol

Intervention Type: DRUG

The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.

Propofol HSK3486

Propofol induction + HSK3486 maintenance group

Group Type: OTHER

Propofol HSK3486

Intervention Type: DRUG

The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.

Interventions

HSK3486

The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.

Intervention Type: DRUG

Propofol

The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.

Intervention Type: DRUG

Propofol HSK3486

The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Inpatients requiring tracheal intubation under general anesthesia and a non-emergent, non-cardiothoracic, non-extracerebral, and non-nasal endoscopic elective surgery for an estimated duration of about 1-6 h, with an bleeding volume of ≤ 1000 mL

2. Aged ≥ 18 and ≤ 65 years old, regardless of gender;

3. American Society of Anesthesiologists (ASA) Class I-III;

4. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2;

5. The vital signs during the screening period meet the following criteria:

• Respiratory rate ≥ 10 and ≤ 24 breaths/min;
• Blood oxygen saturation (SpO2) ≥ 95% when inhaling;
• Systolic blood pressure (SBP) ≥ 90 mmHg and ≤ 160 mmHg;
• Diastolic blood pressure (DBP) ≥ 60 mmHg and ≤ 100 mmHg;
• Heart rate ≥ 55 beats/min and ≤ 100 beats/min;

6. The laboratory parameters measured at screening period reach the following criteria:

• Neutrophil count ≥ 1.5 × 109/L;
• Platelet count ≥ 80 × 109/L;
• Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days);
• ALT and AST ≤ 3.0 × upper limit of normal (ULN);
• Total bilirubin ≤ 1.5 × ULN;
• Serum creatinine ≤ 1.5 × ULN.

7. Subjects who understand the procedures and methods of this study, and are willing to complete the trial in strict accordance with clinical trial protocol and sign the informed consent.

Exclusion Criteria

1. Patients with contraindications to general anesthesia or previous history of anesthesia accidents;

2. Known hypersensitivity to excipients and ingredients found in propofol injection and HSK3486 injectable emulsion (soybean oil, glycerin, triglycerides, egg lecithin, sodium oleate, and sodium hydroxide), benzodiazepines, opioids, rocuronium bromide, and sugammadex sodium; cross-reactivity to halogenated anesthetics, jaundice or unexplained fever from previous use of halogenated anesthetics; contraindications to propofol;

3. Medical history or evidence of any of the following prior to screening, which may increase sedation/anesthesia risk:

• History of cardiovascular disease: Uncontrolled hypertension or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction occurring in almost 6 months prior to screening, and history of tachycardia/bradycardia requiring medication, third-degree atrioventricular block or QTcF ≥ 450 ms (male) or ≥ 470 ms (female) (corrected using Fridericia's formula) during screening period.
• Respiratory system disorders: Respiratory insufficiency, history of bronchospasm requiring treatment within 3 months prior to screening, acute respiratory tract infection with obvious symptoms such as fever, wheezing, or productive cough within 1 week prior to administration of the study drug;
• History of craniocerebral disease: Patient with a history of craniocerebral injury, convulsions, epilepsy, intracranial hypertension, cerebral aneurysm, or cerebrovascular accident; history of schizophrenia, mania, chronic use of antipsychotics, or cognitive impairment.
• Gastrointestinal disease history: Gastrointestinal retention, active hemorrhage, or circumstances that may lead to reflux and aspiration.
• Diabetic patients with uncontrolled blood glucose (fasting blood glucose ≥ 11.1 mmol/L, and/or random blood glucose ≥ 13.6 mmol/L).
• Patients with a history of uncontrolled and clinically significant liver, kidney, blood system, nervous system or metabolic system diseases judged by the investigator to be unsuitable for this trial.
• History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking > 2 units of alcohol (1 unit = 360 mL of beer or 45 mL of liquor with 40% alcohol or 150 mL of wine).
• History of drug abuse within 3 months prior to screening.
• Serious infection, trauma, or major surgery within 4 weeks prior to screening.

4. Any one of the following respiratory risks before/during screening:

• Asthma history, and stridor.
• Sleep apnea syndrome.
• History of malignant hyperthermia or family history.
• History of failed tracheal intubation.
• Judged by the investigator to have difficult airway or judged as difficult tracheal intubation (modified Mallampati score III or IV);

5. Received any of the following drugs or therapies prior to screening:

• Participated in other drug trials within 1 month prior to screening.
• Using the drugs that may affect QT interval within 2 weeks prior to screening.
• Using propofol, other sedatives/anesthetics, and/or opioid analgesics or compounds containing analgesics within 3 days prior to screening.

6. Women who are pregnant or breastfeeding; women of child-bearing potential or men who are unwilling to use contraception during the trial; Subjects who are planning pregnancy within 1 month after the completion of the trial (including male subjects);

7. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Peking University First Hospital

Beijing, , China

Countries

China

Other Identifiers

HSK3486-204

Identifier Type: -

Identifier Source: org_study_id